(Q34699108)

4 August 2017

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens (English)

1 reference

hospital-acquired pneumonia

4 August 2017

gram-positive bacteria

0 references

0 references

1 reference

1 reference

9

Marin H Kollef

1 reference

4 August 2017

2

Tahaniyat Lalani

1 reference

4 August 2017

7

Galia Rahav

1 reference

4 August 2017

3

G Ralph Corey

1 reference

4 August 2017

20

Martin E Stryjewski

1 reference

4 August 2017

18

Steven L Barriere

1 reference

4 August 2017

1

Ethan Rubinstein

1 reference

4 August 2017

17

Fredric C Genter

1 reference

4 August 2017

10

Andrew F Shorr

1 reference

4 August 2017

15

Antoni Torres

1 reference

4 August 2017

19

H David Friedland

1 reference

4 August 2017

Zeina A Kanafani

4

1 reference

4 August 2017

Esteban C Nannini

5

1 reference

4 August 2017

Marcelo G Rocha

6

1 reference

4 August 2017

Michael S Niederman

8

1 reference

4 August 2017

Patrick C Lee

11

1 reference

4 August 2017

Arnold L Lentnek

12

1 reference

4 August 2017

Carlos M Luna

13

1 reference

4 August 2017

Jean-Yves Fagon

14

1 reference

4 August 2017

Michael M Kitt

16

1 reference

4 August 2017

ATTAIN Study Group

21

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

Clinical Infectious Diseases

4 August 2017

1 reference

4 August 2017

52

1 reference

4 August 2017

1

1 reference

4 August 2017

31-40

1 reference

Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.

4 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

Pneumonia caused by methicillin-resistant Staphylococcus aureus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

In vitro activity of telavancin against resistant gram-positive bacteria

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

Prevention of hospital-associated pneumonia and ventilator-associated pneumonia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

In vitro activity of TD-6424 against Staphylococcus aureus

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

Epidemiology of nosocomial pneumonia. New perspectives on an old disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

APACHE II: a severity of disease classification system

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System

7 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ031

The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ031

Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ031

Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIQ031

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3060890

A randomized trial of diagnostic techniques for ventilator-associated pneumonia

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21148517

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21148517

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Nosocomial infections in combined medical-surgical intensive care units in the United States

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21148517

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/CID/CIQ031

1 reference

4 August 2017

1 reference

4 August 2017

1 reference